Ken Griffin Allogene Therapeutics, Inc. Transaction History

Citadel Advisors LLC

$550 Billion
Q2 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 10,252,606 shares of ALLO stock, worth $10.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

10,252,606

Previous 74,400 13680.38%

Holding current value

$10.6 Million

Previous $108,000 10626.85%

% of portfolio

0.0%

Previous 0.0%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	BUY	$0.95 - $1.7 $46,813 - $83,770	49,277 Added 0.48%	10,252,606 $11.6 Million
Q1 2025 May 15, 2025	BUY	$1.4 - $2.84 $6.8 Million - $13.8 Million	4,854,233 Added 90.75%	10,203,329 $14.9 Million
Q4 2024 Feb 14, 2025	BUY	$1.84 - $3.22 $569,483 - $996,596	309,502 Added 6.14%	5,349,096 $11.4 Million
Q3 2024 Nov 14, 2024	BUY	$2.08 - $3.5 $5.39 Million - $9.08 Million	2,593,091 Added 105.99%	5,039,594 $14.1 Million
Q2 2024 Aug 14, 2024	SELL	$2.23 - $4.38 $1.49 Million - $2.92 Million	-666,722 Reduced 21.42%	2,446,503 $5.7 Million
Q1 2024 May 15, 2024	SELL	$2.92 - $5.63 $2.74 Million - $5.29 Million	-940,001 Reduced 23.19%	3,113,225 $13.9 Million
Q4 2023 Feb 14, 2024	SELL	$2.28 - $3.5 $142,281 - $218,414	-62,404 Reduced 1.52%	4,053,226 $13 Million
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $1.98 Million - $3.72 Million	-624,711 Reduced 13.18%	4,115,630 $13 Million
Q2 2023 Aug 14, 2023	BUY	$4.53 - $6.74 $1.78 Million - $2.64 Million	391,838 Added 9.01%	4,740,341 $23.6 Million
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $18.7 Million - $31.3 Million	3,808,199 Added 704.83%	4,348,503 $21.5 Million
Q4 2022 Feb 14, 2023	SELL	$5.62 - $11.11 $1.98 Million - $3.92 Million	-352,551 Reduced 39.49%	540,304 $3.4 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $8.37 Million - $14 Million	811,492 Added 997.37%	892,855 $9.64 Million
Q2 2022 Aug 15, 2022	SELL	$6.78 - $12.28 $17.2 Million - $31.1 Million	-2,534,748 Reduced 96.89%	81,363 $927,000
Q1 2022 May 16, 2022	BUY	$7.65 - $15.29 $1.85 Million - $3.69 Million	241,614 Added 10.18%	2,616,111 $23.8 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $27.1 Million - $50.6 Million	2,064,988 Added 667.18%	2,374,497 $35.4 Million
Q3 2021 Nov 15, 2021	SELL	$21.01 - $27.64 $2.13 Million - $2.8 Million	-101,301 Reduced 24.66%	309,509 $7.95 Million
Q2 2021 Aug 16, 2021	BUY	$23.49 - $35.8 $8.91 Million - $13.6 Million	379,323 Added 1204.7%	410,810 $10.7 Million
Q1 2021 May 17, 2021	SELL	$25.79 - $39.02 $7.02 Million - $10.6 Million	-272,366 Reduced 89.64%	31,487 $1.11 Million
Q4 2020 Feb 16, 2021	BUY	$25.24 - $43.45 $6.07 Million - $10.4 Million	240,364 Added 378.59%	303,853 $7.67 Million
Q3 2020 Nov 16, 2020	SELL	$32.38 - $44.96 $1.1 Million - $1.52 Million	-33,851 Reduced 34.78%	63,489 $2.39 Million
Q2 2020 Aug 14, 2020	BUY	$18.39 - $54.04 $773,373 - $2.27 Million	42,054 Added 76.07%	97,340 $4.17 Million
Q1 2020 May 15, 2020	SELL	$18.22 - $28.25 $17,491 - $27,120	-960 Reduced 1.71%	55,286 $1.07 Million
Q4 2019 Feb 14, 2020	SELL	$24.82 - $31.4 $7.34 Million - $9.28 Million	-295,648 Reduced 84.02%	56,246 $1.46 Million
Q3 2019 Nov 14, 2019	SELL	$26.11 - $32.99 $2.39 Million - $3.02 Million	-91,683 Reduced 20.67%	351,894 $9.59 Million
Q2 2019 Aug 14, 2019	SELL	$25.56 - $31.09 $5.65 Million - $6.87 Million	-220,926 Reduced 33.25%	443,577 $11.9 Million
Q1 2019 May 15, 2019	BUY	$24.82 - $32.54 $7.29 Million - $9.56 Million	293,885 Added 79.3%	664,503 $0
Q4 2018 Feb 14, 2019	BUY	$22.5 - $33.3 $8.34 Million - $12.3 Million	370,618 New	370,618 $9.98 Million

Others Institutions Holding ALLO

# of Institutions

169

Shares Held

162M

Call Options Held

146K

Put Options Held

97.1K

View Full List

About Allogene Therapeutics, Inc.

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $148M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

More about ALLO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account